1000343-69-0

Basic information

• Product Name: 6-BROMO-5-METHYL (1H)INDAZOLE
• Synonyms: 6-BROMO-5-METHYL (1H)INDAZOLE;1H-Indazole, 6-broMo-5-Methyl-;6-broMo-5-Methyl indazole
• CAS NO: 1000343-69-0
• Molecular Formula: C₈H₇BrN₂
• Molecular Weight: 211.05858
• Product Categories: Building Blocks;Indazole;Indazoles
• Mol File: 1000343-69-0.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 344.623 °C at 760 mmHg
• Flash Point: 162.222 °C
• Appearance: /
• Density: 1.654
• Storage Temp.: 2-8°C(protect from light)
• PKA: 13.01±0.40(Predicted)
• CAS DataBase Reference: 6-BROMO-5-METHYL (1H)INDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BROMO-5-METHYL (1H)INDAZOLE(1000343-69-0)
• EPA Substance Registry System: 6-BROMO-5-METHYL (1H)INDAZOLE(1000343-69-0)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 1000343-69-0(Hazardous Substances Data)

Usage

General Description

6-Bromo-5-methyl (1H)indazole is a chemical compound with the molecular formula C8H7BrN2. It is a derivative of indazole, a heterocyclic compound containing a five-membered ring with two nitrogen atoms. The presence of a bromine atom and a methyl group on the indazole ring gives this compound specific chemical and biological properties. It is used as a building block in the synthesis of complex organic molecules, particularly in the pharmaceutical industry for the development of new drugs. 6-BROMO-5-METHYL (1H)INDAZOLE is also being studied for its potential antimicrobial, anti-cancer, and anti-inflammatory properties, making it a subject of interest in medicinal chemistry research.

Upstream product

• 69383-59-1 1-bromo-2,4-dimethyl-5-nitro-benzene 
• 69383-60-4 5-bromo-2,4-dimethylaniline 

Relevant articles and documents

Discovery of 4-Aminoquinoline-3-carboxamide derivatives as potent reversible Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis

A structure-hopping strategy was applied to discover a series of novel 4-aminoquinoline-3-carboxamide derivatives as potent, reversible BTK inhibitors. Compared to the previously described cinnoline scaffold compounds, the 4-aminoquinoline analogues showed significantly improved drug-like properties, especially in their aqueous solubility. The most potent compound, 25, displayed a stronger inhibitory effect on both BTKWT (IC50 = 5.3 nM) and BTKC481S (IC50 = 39 nM). In a rodent collagen-induced arthritis model, compound 25 efficiently reduced paw swelling without a loss in body weight. On the basis of potency, drug-like properties, stability, and noncovalent mode of inhibition, our representative inhibitors could have a promising profile to be treatments for a wide range of autoimmune diseases.

COMPOUNDS FOR INHIBITING LRRK2 KINASE ACTIVITY

Compounds of Formula (I) or pharmaceutically acceptable salt thereof, a pharmaceutical compositions comprising these compounds, the use of these compounds and compositions in the treatment of diseases in which LRRK-2 kinase is involved.

COMPOUNDS

Provided are novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases associated with or characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).